Compare American Homes 4 Rent Class A (AMH) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
American Homes 4 Rent Class A vs Recursion Pharmaceuticals Inc — how do they compare? American Homes 4 Rent Class A trades at $33.92 (market cap $12.28B), while Recursion Pharmaceuticals Inc trades at $3.37 (market cap $1.81B). The key difference: American Homes 4 Rent Class A is far larger — about 6.8× Recursion Pharmaceuticals Inc's market cap, and American Homes 4 Rent Class A pays a 3.87% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| AMH | RXRX | |
|---|---|---|
Market Cap | $12.28B | $1.81B |
Sector | Real Estate | Health |
52-Week High | $35.82 | $6.79 |
52-Week Low | $27.38 | $2.84 |
Enterprise Value | $17.35B | $1.33B |
Dividend Yield | 3.87% | — |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About American Homes 4 Rent Class A
American Homes 4 Rent is a real estate investment trust primarily focused on acquiring, operating, and leasing single-family homes as rental properties throughout the United States. The company's real estate portfolio is largely comprised of single-family properties in urban markets in the Southern and Midwestern regions of the U.S. American Homes 4 Rent's land holdings also represent a sizable percentage of its total assets in terms of value. The company derives the vast majority of its income in the form of rental revenue from single-family properties through short-term or annual leases. The firm's largest geographical markets include Dallas, Texas
Read more on AMH →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
